Evidence map›Paper›PMID 28436977›Full record

ArticleBone marrow transplantation2017

Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

A Hamblin, D M Greenfield, M Gilleece, N Salooja, M Kenyon, E Morris, N Glover, P Miller, H Braund, A Peniket and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 2 countries.

A HamblinOxford BRC Haematology Theme, Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
D M GreenfieldDepartment of Clinical Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
M GilleeceDepartment of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
N SaloojaDepartment of Haematology, Hammersmith Hospital, London, UK.
M KenyonDepartment of Haematological Medicine, King's College Hospital, London, UK.
E MorrisDepartment of Immunology, Royal Free London NHS Foundation Trust and UCL Medical School, London, UK.
N GloverLondon Cancer Alliance, London, UK.
P MillerAnthony Nolan, London, UK.
H BraundAnthony Nolan, London, UK.
A PeniketOxford BRC Haematology Theme, Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
B E ShawCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J A SnowdenDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Anthony Nolan · GBUniversity of Oxford · GBHammersmith Hospital · GBKing's College Hospital · GBLeeds Teaching Hospitals NHS Trust · GBLondon Cancer · GBMedical College of Wisconsin · USSheffield Teaching Hospitals NHS Foundation Trust · GBUniversity College London · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite international guidelines, optimal delivery models of late effects (LE) services for HSCT patients are unclear from the clinical, organizational and economic viewpoints. To scope current LE service delivery models within the UK NHS (National Health Service), in 2014, we surveyed the 27 adult allogeneic HSCT centres using a 30-question online tool, achieving a 100% response rate. Most LE services were led and delivered by senior physicians (>80% centres). Follow-up was usually provided in a dedicated allograft or LE clinic for the first year (>90% centres), but thereafter attrition meant that only ~50% of patients were followed after 5 years. Most centres (69%) had a standard operating procedure for long-term monitoring but access to a LE Multi-Disciplinary Team was rare (19% centres). Access to medical specialities necessary for LE management was good, but specialist interest in long-term HSCT complications was uncommon. Some screening (endocrinopathy, cardiovascular) was near universal, but other areas were more limited (mammography, cervical smears). Funding of extra staff and investigations were the most commonly perceived barriers to implementation of LE services. This survey shows variation in the long-term follow-up of allogeneic HSCT survivors within the UK NHS and further work is warranted to optimize effective, sustainable and affordable models of LE service delivery among this group.

Indexed as

Delivery of Health CareHematopoietic Stem Cell TransplantationMonitoring, PhysiologicAdolescentAdultAllograftsDisease-Free SurvivalFemaleHumansMaleSurvival RateUnited Kingdom

Identifiers

PMID28436977
OpenAlexW2609194520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.